Document:

EX-10.15

 Exhibit 10.15 

LOGICBIO THERAPEUTICS, INC. 

AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT 

This Amended and Restated Employment Agreement (this “Agreement”) is entered into as of the last date set forth on the
signature page below (the “Effective Date”) by and between LogicBio Therapeutics, Inc. (the “Company”) and Tom Wilton (“Executive”). 

1. Duties and Scope of Employment. 

(a) Positions and Duties. The Company hereby agrees to continue to employ Executive as its Chief Business Officer, and Executive will
hereby agrees to continue in such position and serve the Company in such capacity, during the Employment Term. Executive will render such business and professional services in the performance of his duties, consistent with Executive’s position
within the Company, as will reasonably be assigned to Executive by the Company’s President and Chief Executive Officer (the “CEO”). The period of Executive’s employment under this Agreement is referred to herein as the
“Employment Term.” 
 (b) Obligations. During the Employment Term, Executive will perform his duties faithfully and
to the best of his ability and will devote his full business efforts and time to the Company. For the duration of the Employment Term, Executive agrees not to actively engage in any other employment, occupation, or consulting activity for any direct
or indirect remuneration without the prior approval of the CEO or the Company’s Board of Directors (the “Board”). 
 2.
At-Will Employment. The parties agree that Executive’s employment with the Company will continue to be “at-will” employment and may be terminated
at any time with or without cause or notice. However, as described in this Agreement, Executive may be entitled to severance benefits depending on the circumstances of Executive’s termination of employment with the Company. 

3. Compensation. 
 (a)
Base Salary. During the Employment Term, the Company will pay Executive an annual salary (the “Base Salary”) of $335,000 as compensation for Executive’s services. The Base Salary will be paid periodically in accordance
with the Company’s normal payroll practices. Executive’s Base Salary will be subject to review by the Compensation Committee (the “Compensation Committee”) of the Board and adjustments to the Base Salary may be made in its
discretion. 
 (b) Bonus. During the Employment Term, Executive will be eligible to receive an annual bonus, with a target annual
bonus equal to thirty-five percent (35%) of the Base Salary, upon achievement of certain performance objectives to be determined by the Compensation Committee. The amount, terms and conditions of any annual bonus will be determined by the
Compensation Committee in its discretion and any annual bonus will be subject to the terms and conditions of the applicable Company bonus plan, as in effect from time to time. Any earned annual bonus will be paid as soon as reasonably practicable
after the Compensation Committee determines that such bonus has been earned, but in no event shall the bonus be paid after the March 15th following the end of the calendar year to which the bonus
relates, in accordance with the Company’s normal payroll practices. The payment of any annual bonus will be subject to Executive’s continued employment through the payment date, except as set forth in Section 6 or 7 below or as
otherwise provided in an applicable bonus plan. 

  

 (c) Equity Compensation. During the Employment Term, Executive will be eligible to
receive equity and equity-based awards in the discretion of the Board or the Compensation Committee and on such terms and conditions as are determined by the Board or the Compensation Committee in its discretion. Any equity and equity-based awards
granted to Executive, whether before or after the Effective Date, will be governed by the terms and conditions of the applicable Company equity incentive plan(s), as in effect from time to time, and the award agreements governing such equity or
equity-based awards (any such plan and award agreements, collectively, the “Equity Agreements”). 
 (d) Employee
Benefits. During the Employment Term, Executive will be entitled to participate in the employee benefit plans maintained by the Company as in effect from time to time of general applicability to other senior executives of the Company. The
Company reserves the right to cancel or change any of its employee benefit plans at any time. 
 (e) Indemnification. Executive will
be entitled to the same indemnification rights as the Company grants to other senior executives of the Company, subject to the provisions of the Company’s by-laws and certificate of incorporation. 

4. Vacation. Executive will be entitled to earn paid annual vacation in accordance with Company policy for other senior executive
officers, as in effect from time to time. 
 5. Expenses. 

(a) Subject to Section 5(b), the Company will reimburse Executive for all reasonable and necessary expenses incurred by Executive in
connection with the performance of Executive’s duties hereunder. 
 (b) Subject to any applicable policy established by the Company as
in effect from time to time, the Company will reimburse Executive for expenses incurred pursuant to Section 5(a) upon Executive’s having submitted valid receipts to the Company, provided that Executive is an employee of the Company on the
date on which the expenses are incurred. Executive’s right to payment or reimbursement for expenses hereunder shall be subject to the following additional rules: (i) the amount of expenses eligible for payment or reimbursement during any
calendar year shall not affect the expenses eligible for payment or reimbursement in any other calendar year, (ii) payment or reimbursement shall be made not later than December 31 of the calendar year following the calendar year in which
the expense or payment was incurred, and (iii) the right to payment or reimbursement is not subject to liquidation or exchange for any other benefit. 

(c) In the event of that Executive’s employment with the Company (or any parent or subsidiary or successor of the Company) is terminated
by the Company for Cause or by Executive without Good Reason prior to September 7, 2019, Executive agrees to repay to the Company, within thirty (30) days of the date of termination of Executive’s employment, an amount equal to fifty
percent (50%) of the Relocation Payments (as such term is defined in the Employment Agreement by and between the Company and Executive, entered into as of August 6, 2017). 

  
 -2- 

 6. Severance. 

(a) Termination for other than Cause, Death or Disability or Resignation for Good Reason. If the Company (or any parent or subsidiary or
successor of the Company) terminates Executive’s employment with the Company other than for Cause (as defined below) and other than due to Executive’s death or Disability (as defined below), or Executive resigns with Good Reason (as
defined below), then, subject to Section 8, Executive will be entitled to (i) receive severance pay at a rate equal to Executive’s Base Salary, as then in effect, for six (6) months from the date of such termination, which will
be paid in equal installments in accordance with the Company’s normal payroll practices; (ii) an amount equal to Executive’s target annual bonus for the year in which such termination of employment occurs, multiplied by .5, payable in
equal installments in accordance with the Company’s normal payroll practices over six (6) months from the date of such termination; and (iii) if Executive elects continuation coverage pursuant to the Consolidated Omnibus Budget
Reconciliation Act of 1985, as amended (“COBRA”) for Executive and his eligible dependents within the time period prescribed pursuant to COBRA, the Company will reimburse Executive for the COBRA premiums for such coverage until the
earlier of (A) a period of three (3) months from the last date of employment of Executive with the Company, or (B) the date upon which Executive ceases to be eligible for coverage under COBRA. COBRA reimbursements will be made by the
Company to Executive consistent with the Company’s normal expense reimbursement policy. However, if the Company determines in its sole discretion that it cannot provide the foregoing COBRA benefits without potentially violating applicable law
(including, without limitation, Section 2716 of the Public Health Service Act) or incurring additional taxes, the Company will in lieu thereof provide to Executive a taxable monthly payment in an amount equal to the monthly COBRA premium that
Executive would be required to pay to continue his group health coverage in effect on the date of his termination of employment (which amount will be based on the premium for the first month of COBRA coverage) for the time period described in clause
(A) in equal installments in accordance with the Company’s normal payroll practices. In addition to the amounts described above, Executive will be entitled to receive Executive’s accrued and unpaid Base Salary through the date
Executive’s employment terminates, any unreimbursed expenses due under Section 5 of above, and any vested benefits required to be paid or provided under the terms and conditions of the Company’s benefit plans (collectively, the
“Accrued Benefits”) if Executive’s employment terminates in the circumstances described in this Section 6(a). 

(b) Termination for Cause or Death or Disability; Voluntary Resignation. If Executive’s employment with the Company (or any parent
or subsidiary or successor of the Company) is terminated voluntarily by Executive without Good Reason, for Cause by the Company or due to Executive’s death or Disability, then Executive will be entitled to receive the Accrued Benefits and no
further compensation or benefits will be paid to Executive under this Agreement. 
 (c) Exclusive Remedy. In the event of a
termination of Executive’s employment with the Company (or any parent or subsidiary or successor of the Company), the provisions of this Section 6 and Section 7 below are intended to be and are exclusive and in lieu of any other
rights or remedies to which Executive or the Company may otherwise be entitled in connection with the termination of Executive’s employment under any employee compensation or benefit plan which provides benefits in the nature of severance or
continuation pay. 

  
 -3- 

 7. Termination for other than Cause, Death or Disability or Resignation for Good Reason
within 24 months following a Change in Control. If the Company (or any parent or subsidiary or successor of the Company) terminates Executive’s employment with the Company other than for Cause (as defined below) and other than due to
Executive’s death or Disability (as defined below), or Executive resigns with Good Reason (as defined below), in either case, within twenty-four (24) months following a Change of Control (as defined below) then, subject to Section 8
and in lieu of the payments set forth in Section 6 above, Executive will be entitled to (i) receive a severance payment equal to one times (1x) the sum of (A) Executive’s annual Base Salary, as then in effect, and
(B) Executive’s target annual bonus for the year in which such termination of employment occurs (ii) an amount equal to the monthly COBRA premium that Executive would be required to pay to continue his group health coverage in effect
on the date of his termination of employment for a period of nine (9) months (which amount will be based on the premium for the first month of COBRA coverage); and (iv) accelerated vesting as to one hundred percent (100%) of
Executive’s then outstanding and unvested equity and equity-based awards (with any performance-vesting awards vesting at target levels). All amounts payable under prongs (i) and (ii) of this Section 7 will be paid in a lump sum on the
first normal payroll date of the Company following the Release Deadline (as defined below) in accordance with the Company’s normal payroll practices. In addition to the amounts described above, Executive will be entitled to receive the Accrued
Benefits. 
 8. Conditions to Receipt of Severance; No Duty to Mitigate. 

(a) Separation Agreement and Release of Claims. The receipt of any severance pursuant to Sections 6 or 7 will be subject to Executive
signing and not revoking a separation agreement and general release of claims in a form reasonably satisfactory to the Company (the “Release”) and provided that such Release becomes effective and irrevocable no later than sixty
(60) days following the termination date (such deadline, the “Release Deadline”). If the Release does not become effective and irrevocable by the Release Deadline, Executive will forfeit any rights to severance or benefits
under this Agreement. In no event will severance payments or benefits be paid or provided until the Release becomes effective and irrevocable. Subject to Section 8(b), any cash severance pay to which Executive is entitled pursuant to
Section 6 or 7 (other than the Accrued Obligations) will be paid, or will begin to be paid, on the first normal payroll date of the Company following the Release Deadline, with such payment to include all amounts that would have been paid prior
to such date but for this Section 8(a). 
 (b) Section 409A.  

(i) Notwithstanding anything to the contrary in this Agreement, no severance pay or benefits to be paid or provided to Executive, if any,
pursuant to this Agreement that, when considered together with any other payments or benefits, would be considered deferred compensation under Code Section 409A and the final regulations and any guidance promulgated thereunder (collectively,
“Section 409A”) (together, the “Deferred Payments”) will be paid or otherwise provided until Executive has incurred a “separation from service” within the meaning of Section 409A.

  

  
 -4- 

 (ii) Notwithstanding anything to the contrary in this Agreement, if Executive is a
“specified employee” within the meaning of Section 409A at the time of Executive’s termination (other than due to death), then the Deferred Payments that are payable within the first six (6) months following Executive’s
separation from service, will become payable on the first payroll date that occurs on or after the date six (6) months and one (1) day following the date of Executive’s separation from service. All subsequent Deferred Payments, if
any, will be payable in accordance with the payment schedule applicable to each payment or benefit. Notwithstanding anything herein to the contrary, if Executive dies following Executive’s separation from service, but prior to the six
(6) month anniversary of the separation from service, then any payments delayed in accordance with this paragraph will be payable in a lump sum as soon as administratively practicable after the date of Executive’s death and all other
Deferred Payments will be payable in accordance with the payment schedule applicable to each payment or benefit. Each payment and benefit payable under this Agreement is intended to constitute a separate payment for purposes of Section 1.409A-2(b)(2) of the Treasury Regulations. 
 (iii) Any amounts paid under this Agreement
that satisfies the requirements of the “short-term deferral” rule set forth in Section 1.409A-1(b)(4) of the Treasury Regulations will not constitute Deferred Payments for purposes of clause
(i) above. 
 (iv) Any amount paid under this Agreement that qualifies as a payment made as a result of an involuntary separation from
service pursuant to Section 1.409A-1(b)(9)(iii) of the Treasury Regulations that does not exceed the Section 409A Limit (as defined below) will not constitute Deferred Payments for purposes of clause
(i) above. 
 (v) All payments under this Agreement are intended to be exempt from, or comply with, the requirements of
Section 409A so that none of the payments and benefits provided hereunder will be subject to the additional tax imposed under Section 409A, and any ambiguities herein will be interpreted to so comply. The Company and Executive agree to
work together in good faith to consider amendments to this Agreement and to take such reasonable actions which are necessary, appropriate or desirable to avoid imposition of any additional tax or income recognition prior to actual payment to
Executive under Section 409A. In no event will the Company, any of its subsidiaries or affiliates be liable to Executive by reason of any acceleration of income or any additional tax (including any interest and penalties) asserted with respect
to the failure of any payments or benefits provided under this Agreement to satisfy the applicable requirements of Section 409A. 
 (c)
Confidential Information Agreement. Executive’s continuing receipt of any payments or benefits under Section 6 or 7 will be subject to Executive continuing to comply with the terms of Confidential Information Agreement (as defined
in Section 11). In the event Executive breaches the provisions of the Confidential Information Agreement, then all payments and benefits to which Executive may otherwise be entitled pursuant to Sections 6 or 7 will immediately cease. 

(d) No Duty to Mitigate. Executive will not be required to mitigate the amount of any payment contemplated by this Agreement, nor will
any earnings that Executive may receive from any other source reduce any such payment. 
  

  
 -5- 

 9. Definitions. 

(a) Cause. For purposes of this Agreement, “Cause” is defined, as determined by the Company in its reasonable judgment,
as (i) breach of this Agreement or the Confidential Information Agreement by Executive; (ii) intentional and continued nonperformance or misperformance of Executive’s duties or refusal to abide by or comply with the reasonable
directives of the CEO or the Board, or the Company’s policies and procedures, which, if reasonably susceptible to cure (as determined by the Company), is not cured within fifteen (15) days following Executive’s receipt of written
notice from the Company describing in reasonable detail the nature of the nonperformance, misperformance or refusal, as applicable; (iii) Executive’s gross negligence in the performance of his material duties under this Agreement;
(iv) Executive’s fraud or willful misconduct with respect to the business or affairs of the Company; (v) Executive’s conviction of, or a plea of nolo contendere to, a felony or other crime involving moral turpitude; or
(vi) the commission of any act in direct or indirect competition with or materially detrimental to the best interests of Company. 
 (b)
Change of Control. For purposes of this Agreement, “Change of Control” is defined as: 
 (i) the acquisition of the
Company by another entity by means of any transaction or series of related transactions (including, without limitation, any reorganization, merger or consolidation or stock transfer, but excluding any such transaction effected primarily for the
purpose of changing the domicile of the Company), unless the Company’s stockholders of record immediately prior to such transaction or series of related transactions hold, immediately after such transaction or series of related transactions, at
least fifty percent (50%) of the voting power of the surviving or acquiring entity (provided that the sale by the Company of its securities for the primary purpose of raising additional funds shall not constitute a Change of Control
hereunder); or 
 (ii) a sale, license or other disposition of all or substantially all of the assets, intellectual property or technology
of the Company. 
 Notwithstanding the foregoing provisions of this definition, a transaction will not be deemed a Change of Control unless
the transaction qualifies as a “change in control event” within the meaning of Section 409A. 
 (c) Code. For purposes
of this Agreement, “Code” means the Internal Revenue Code of 1986, as amended. 
 (d) Disability. For purposes of
this Agreement, “Disability” means that Executive has been unable to perform Executive’s Company duties as the result of Executive’s incapacity due to physical or mental illness for at least
twenty-six (26) weeks after the commencement of such incapacity or for one-hundred and eighty (180) days in any consecutive twelve (12) month period,
which incapacity is determined by a physician selected by the Company or its insurers and acceptable to Executive or Executive’s legal representative (such agreement as to acceptability not to be unreasonably withheld). 

(e) Good Reason. For purposes of this Agreement, “Good Reason” means Executive’s resignation within thirty
(30) days following the expiration of any Company cure period (described below) following the occurrence of one or more of the following, without Executive’s consent: 

(i) a material diminution of Executive’s authority, duties, or responsibilities with the Company in effect immediately prior to such
assignment; 

  
 -6- 

 (ii) a material breach of this Agreement by the Company; or 

(iii) a material reduction in Executive’s base salary in effect immediately prior to such termination, unless the Company also similarly
reduces the base salaries of all other similarly-situated employees of the Company. 
 Executive will not resign for Good Reason without first providing the
Company with written notice of the acts or omissions constituting the grounds for “Good Reason” within ninety (90) days of the initial existence of the grounds for “Good Reason” and a cure period of thirty (30) days
following the date of such notice. 
 (f) Section 409A Limit. For purposes of this Agreement,
“Section 409A Limit” will mean two (2) times the lesser of: (i) Executive’s annualized compensation based upon the annual rate of pay paid to Executive during Executive’s taxable year preceding
Executive’s taxable year of his separation from service as determined under Treasury Regulation Section 1.409A-1(b)(9)(iii)(A)(1) and any Internal Revenue Service guidance issued with respect
thereto; or (ii) the maximum amount that may be taken into account under a qualified plan pursuant to Section 401(a)(17) of the Internal Revenue Code for the year in which Executive’s separation from service occurred. 

10. Limitation on Payments. 

(a) If Executive receives, is provided or may receive or be provided any payment or benefit that constitutes a “parachute payment”
(as defined in Section 280G(b)(2) of the Code), and the net after-tax amount of any such parachute payment is less than the net after-tax amount if the aggregate
payments and benefits to be made to Executive were three times Executive’s “base amount” (as defined in Section 280G(b)(3) of the Code), less $1.00, then the aggregate of the amounts constituting the parachute payments shall be
reduced to an amount equal to three times Executive’s base amount, less $1.00. For purposes of determining the “net after-tax amount,” the Company will cause to be taken into account all
applicable federal, state and local income and employment taxes and the excise taxes (all computed at the highest applicable marginal rate, net of the maximum reduction in federal income taxes which could be obtained from a deduction of such state
and local taxes). If a reduction pursuant to this Section 10 is to occur, (x) Executive will have no rights to any additional payments and/or benefits that are being reduced, and (y) reduction in payments and/or benefits will occur in
the following order: (i) reduction of cash payments, if any, which shall occur in reverse chronological order such that the cash payment owed on the latest date following the occurrence of the event triggering such excise tax will be the first
cash payment to be reduced; (ii) cancellation of accelerated vesting of equity awards other than stock options, if any; (iii) cancellation of accelerated vesting of stock options, if any; and (iv) reduction of other payments or
benefits, if any, paid or provided to Executive, which shall occur in reverse chronological order such that the payment or benefit owed on the latest date following the occurrence of the event triggering such excise tax will be the first benefit to
be reduced. In the event that acceleration of vesting of equity awards or stock options is to be reduced, such acceleration of vesting will be cancelled in the reverse order of the date of grant. If two or more equity awards or stock options are
granted on the same date, each award or stock option will be reduced on a pro-rata basis. Notwithstanding, any excise tax imposed will be solely the responsibility of Executive. In no event shall Executive
have any discretion with respect to the ordering of his payment reductions. 

  
 -7- 

 (b) Unless the Company and Executive otherwise agree in writing, any determination required
under this Section 10 will be made in writing by a nationally recognized firm of independent public accountants selected by the Company, the Company’s legal counsel or such other person or entity to which the Parties mutually agree (the
“Firm”), whose determination will be conclusive and binding upon Executive and the Company for all purposes. For purposes of making the calculations required by this Section 10, the Firm may make reasonable assumptions and
approximations concerning applicable taxes and may rely on reasonable, good faith interpretations concerning the application of Sections 280G and 4999 of the Code. The Company and Executive will furnish to the Firm such information and documents as
the Firm may reasonably request in order to make a determination under this Section 10. The Company will bear all costs the Firm may reasonably incur in connection with any calculations contemplated by this Section 10. 

11. Confidential Information. Executive agrees that Executive will continue to be bound by the Confidential Information, Invention
Assignment, Restricted Activities, and Arbitration Agreement (the “Confidential Information Agreement”) by and between Executive and the Company in accordance with its terms. 

12. Assignment. This Agreement will be binding upon and inure to the benefit of (a) the heirs, executors and legal representatives
of Executive upon Executive’s death and (b) any successor of the Company. Any such successor of the Company will be deemed substituted for the Company under the terms of this Agreement for all purposes. For this purpose,
“successor” means any person, firm, corporation or other business entity which at any time, whether by purchase, merger or otherwise, directly or indirectly acquires all or substantially all of the assets or business of the Company.
None of the rights of Executive to receive any form of compensation payable pursuant to this Agreement may be assigned or transferred except by will or the laws of descent and distribution. Any other attempted assignment, transfer, conveyance or
other disposition of Executive’s right to compensation or other benefits will be null and void. 
 13. Notices. All notices,
requests, demands and other communications called for hereunder will be in writing and will be deemed given (i) on the date of delivery if delivered personally, (ii) one (1) day after being sent by a well established commercial overnight
service, or (iii) four (4) days after being mailed by registered or certified mail, return receipt requested, prepaid and addressed to the parties or their successors at the following addresses, or at such other addresses as the parties may
later designate in writing: 
 If to the Company: 

LogicBio Therapeutics, Inc. 
 700
Main Street 
 Cambridge, Massachusetts 02139 

If to Executive: 
 at the last
residential address known by the Company. 

  
 -8- 

 14. Severability. In the event that any provision hereof becomes or is declared by a
court of competent jurisdiction to be illegal, unenforceable or void, this Agreement will continue in full force and effect without said provision. 

15. Arbitration. Executive agrees that any and all controversies, claims, or disputes with anyone (including the Company and any
employee, officer, director, stockholder or benefit plan of the Company in their capacity as such or otherwise) arising out of, relating to, or resulting from Executive’s service to the Company, shall be subject to arbitration in accordance
with the provisions of the Confidential Information Agreement. 
 16. Integration. This Agreement represents the entire agreement and
understanding between the parties as to the subject matter herein and supersedes all prior or contemporaneous agreements whether written or oral. This Agreement may be modified only by agreement of the parties by a written instrument executed by the
parties that is designated as an amendment to this Agreement. 
 17. Waiver of Breach. The waiver of a breach of any term or provision
of this Agreement, which must be in writing, will not operate as or be construed to be a waiver of any other previous or subsequent breach of this Agreement. 

18. Headings. All captions and section headings used in this Agreement are for convenient reference only and do not form a part of this
Agreement. 
 19. Tax Withholding. All payments made pursuant to this Agreement will be subject to withholding of applicable taxes and
other legally required amounts. 
 20. Governing Law. This Agreement will be governed by the laws of the Commonwealth of Massachusetts
without regard to any conflict of laws principles that would result in the application of the laws of any other jurisdiction. Executive agrees to submit to the exclusive jurisdiction of the courts of or in the Commonwealth of Massachusetts in
connection with any dispute arising out of this Agreement. 
 21. Acknowledgment. Executive acknowledges that he has had the
opportunity to discuss this matter with and obtain advice from his private attorney, has had sufficient time to, and has carefully read and fully understands all the provisions of this Agreement, and is knowingly and voluntarily entering into this
Agreement. 
 22. Counterparts. This Agreement may be executed in counterparts, and each counterpart will have the same force and
effect as an original and will constitute an effective, binding agreement on the part of each of the undersigned. 
 [Signature Page
Follows.] 

  
 -9- 

 IN WITNESS WHEREOF, each of the parties has executed this Agreement, in the case of the
Company by their duly authorized officers, as of the day and year written below. 
 COMPANY: 

 

							
	LOGICBIO THERAPEUTICS, INC.	  		  	
				
	By:	 	  
	  	Date:	  	  

	Name:	 	Frederic Chereau	  		  	
	Title:	 	President & Chief Executive Officer	  		  	
			
	EXECUTIVE:	  		  	
	  
	  	Date:	  	  

	Tom Wilton	  		  	

 Signature Page To Executive Employment AgreementExhibit 10.1

 

SECOND AMENDMENT TO AGREEMENT OF SALE

 

THIS SECOND AMENDMENT
TO AGREEMENT OF SALE (“Second Amendment”), is made and entered into on this 8th day of October, 2018,
by and between BLONDER TONGUE LABORATORIES, INC., as Seller and JAKE BROWN RD, LLC, as Buyer.

 

Background

 

A. Seller and Buyer entered
into an Agreement of Sale dated August 3, 2018 (the “Original Agreement”) for the sale and purchase of real
property identified as (i) 19.407 acres of land, together with all rights, easements and interests appurtenant thereto, situate
at Lot 8, Block 9000, also known as 1 Jake Brown Road, Old Bridge Township, New Jersey 08857 (the “Land”);
and (ii) all improvements located thereon, including, but not limited to, a commercial building consisting of approximately 128,747
square feet (“the “Building,” and Land and Building, collectively, the “Property”)
and more particularly described on Exhibit “A” attached to the Original Agreement, as amended by Seller’s letter
dated September 20, 2018, which extended the Due Diligence Period expiration date, at Buyer’s request, to October 4, 2018
(the “First Amendment.”). The Original Agreement, as amended by the First Amendment is referred to herein as
the “Agreement”).

 

B. Buyer has now requested
an extension of the Closing Date and Seller has requested certain consideration from Buyer in order to agree to Buyer’s request.

 

NOW, THEREFORE,
the parties, intending to be legally bound agree that, in exchange for the consideration described below, the Agreement shall,
notwithstanding anything therein to the contrary, be modified as follows:

 

1. All capitalized
terms use in this Second Amendment and not otherwise defined herein shall have the same meanings as ascribed to them in the Agreement.

 

2. The parties acknowledge
that the Due Diligence Period has expired as of 4:00 NY time on October 8, 2018 (the “Due Diligence Expiration”)
and Buyer intends to proceed to Closing subject to the fulfillment by Seller of all conditions of Closing required by the Agreement.
Seller acknowledges that Buyer has not yet received a survey performed for Buyer’s behalf and that Seller remains obligated
to address any exceptions to title raised by the title company or Buyer’s lender as a result of said survey which would prevent
a title company from removing the survey exception form the title insurance policy, as and to the extent required by the Agreement.

 

3. The Closing shall
occur or before January 10, 2019, TIME BEING OF THE ESSENCE; provided that Buyer shall have a one-time right to extend the
Closing Date up to an additional 20 calendar days on the condition that (i) written notice of such extension is provided to the
Seller on or before 5:00 p.m. New York Time on January 4, 2019 (“Extension Notice Date”), (ii) such written
notice is accompanied by the wire transfer of an additional amount of $150,000 (the “Extension Deposit”), to
be paid on the Extension Notice Date directly into Sellers designated bank account into which the Second Deposit is required to
be deposited under Section 4 below, and (iii) such Extension Deposit shall become non-refundable in all events if there is a failure
to close for any reason.

 

4. The Second Deposit
shall be funded, no later than close of business on October 9, 2018, by Buyer by wire transfer of immediately available funds directly
into Seller’s designated bank account, the details and wire transfer instructions of which are set forth in the Escrow Release
Authorization attached as Exhibit “A” hereto.

 

5. The parties shall,
simultaneously with the execution of this Second Amendment, execute the Release Authorization attached as Exhibit “A”
hereto, which directs the Escrow Agent to wire transfer the First Deposit funds into Seller’s designated bank account no
later than the close of business on October 9, 2018 and shall each forward the fully executed Escrow Release Authorization to the
Escrow Agent by electronic mail.

 

     

     

    

 

6. Buyer further acknowledges
and agrees that, as of the Due Diligence Expiration, the Deposit is Seller’s property, subject to an obligation to return
an amount equal to the Deposit as set forth in Section 8 below, to be used at Seller’s discretion and subject to no restrictions.
Buyer shall not be entitled to any interest on such funds at Closing and Seller shall not be required to provide an accounting
of the use of the Deposit to Buyer. The parties agree to execute the memorandum of the Agreement in the form attached as Exhibit
“B” hereto and send the original of such memorandum to Escrow Agent to record said memorandum. Seller agrees to
execute any further documents which may be required to record the memorandum and shall have any and all documents required to execute
the memorandum properly notarized as may be required to record same within three (3) business days of Buyer’s request for
same.

 

7. Seller acknowledges
that Buyer has identified the possible need for certain repairs to the parking lot which in aggregate Seller has estimated will
cost up to $60,000 and certain repairs to the lower roof of the Building which in aggregate Buyer has estimated will cost up to
$160,000 (the “Property Repairs”). The Property Repairs constitute “CapX Expense” under and as defined
in Section 3.08(d) of the Lease. Buyer agrees that, in the event Buyer’s lender requires, as a condition of financing the
transaction, the establishment of an escrow at Closing in the amount of the cost estimate of the Property Repairs, as such estimate
may be modified by further agreement of the parties and the Buyer’s lender, that Seller shall pay, from the Purchase Price,
its allocated share of such CapX Expense, as contemplated by the Lease.

 

8. Section 6.01 of
the Agreement is deleted in its entirety and replaced with the following:

 

If Seller defaults hereunder, including
a failure by Seller to fulfill a condition to closing as required in this Agreement of Sale, Buyer shall have the right as its
sole remedy to choose to either (a) terminate this Agreement and be paid by Seller, no later than five (5) business days after
Seller’s receipt of Buyer’s written request therefor, $500,000 in the amount of liquidated damages plus any and all
legal costs and expenses to collect same if Seller does not comply with Buyer’s request for the liquidated damages, or (b)
seek specific performance of Seller’s obligations hereunder.

 

9. Except to the extent
explicitly modified herein, all terms and conditions of the Agreement shall otherwise remain in full force and effect.

 

	:	SELLER:
	 	 
	 	BLONDER
    TONGUE LABORATORIES, INC.
	 	 
	 	By:	 
	 	Name:	Robert J. Pallé, Chief Executive Officer
	 	 	 
	:
    	BUYER:
	 	 	 
	 	JAKE
    BROWN RD, LLC
	 	 	 
	 	By:
    	 
	 	Name:	Arvee Claravall
	 	Title:	CFO

 

     

     

    

 

EXHIBIT
“A”

 

ESCROW
RELEASE AUTHORIZATION

 

October 8, 2018

 

Riverside Abstract

Attention: Azi Mindick

 

		Re:	Agreement of Sale dated August 3, 2018 between Blonder
Tongue Laboratories, Inc. as Seller and Jake Brown Rd, LLC as Buyer, as amended.

 

Reference is made to the Agreement of Sale referred to above
and specifically the provisions of Article Thirteen thereof relating to the duties of the Escrow Agent. Capitalized terms used
but not defined herein shall have the meanings ascribed to them in the Agreement of Sale.

 

The undersigned hereby jointly direct the
Escrow Agent to immediately distribute, no later than close of business on October 9, 2018, the amount of $250,000 plus any accrued
interest, via wire transfer funds, to Blonder Tongue Laboratories, Inc. in accordance with the following wiring instructions:

 

	 	Bank Name:	Sterling National Bank
	 	Address:	400 Rella Blvd., Suite 308
	 	ABA#:	221970443
	 	Account Name:	Blonder Tongue Laboratories, Inc.
	 	Account #:	6700074809

 

Upon disbursal, the balance of the Escrow will be $0.00.

 

IN WITNESS WHEREOF, the undersigned
has executed this Escrow Release Authorization as of the date first above written.

 

	JAKE BROWN RD, LLC,

a New Jersey limited liability company	 
	 	 	 
	By:	 	 
	 	Arvee Claravall, CFO	 
	 	 	 
	BLONDER TONGUE LABORATORIES, INC.,

a Delaware corporation	 
	 	 	 
	By: 	 	 
	 	Robert J. Pallé, Chief Executive Officer	 

 

     

     

    

 

EXHIBIT “B”

 

Return to:

 

Jeffrey Dayon, Esq.

Montgomery McCracken Walker & Rhoads
LLP

437 Madison Avenue

New York, NY 10022

 

		Property:	One Jake Brown Road, Lot 8 of Block 9000, Old Bridge Township,
Middlesex County

 

MEMORANDUM OF AGREEMENT OF SALE

 

KNOW ALL MEN BY THESE
PRESENTS that Blonder Tongue Laboratories, Inc. (hereinafter referred to as “Seller”) has entered into a certain Agreement
of Sale (“Agreement”) with Jake Brown Rd, LLC (“Buyer”) dated August 3, 2018, pertaining to (i) a certain
piece or parcel of land consisting of 19.407 acres, together with all rights, easements and interests appurtenant thereto, situate
at Lot 8, Block 9000, also known as 1 Jake Brown Road, Old Bridge Township, New Jersey; and (ii) all improvements located thereon,
including, but not limited to, a commercial building consisting of approximately 128,747 square feet and more particularly described
on Exhibit “A” attached hereto (hereinafter the “Property”).

 

The parties agree that,
to the extent there is a wrongful failure to discharge this Memorandum of Agreement of Sale from title by Buyer, Seller shall be
entitled to be reimburse by Buyer for Seller’s legal and other costs and expenses incurred by Seller to have the Memorandum
discharged or otherwise removed from title to the Property.

 

This Memorandum is
intended for recording purposes only, and, except to the extent explicitly set forth herein, does not add to, diminish, amend or
modify said Agreement in any respect.

 

IN WITNESS WHEREOF,
the undersigned have executed this Memorandum of Agreement of Sale, this 8th day of October, 2018.

 

	ATTEST:	SELLER:
	 	 
	 	BLONDER TONGUE LABORATORIES, INC.
	 	 	 
	 	By:	                                    
	 	Name:	 
	 	Title:	 
	 	 	 
	ATTEST: 	BUYER:
	 	 
	 	JAKE BROWN RD, LLC
	 	 	 
	 	By:	 
	 	Name:	 
	 	Title:	 

 

     

     

    

 

	STATE OF NEW JERSEY	:
	 	:  ss
	COUNTY OF MIDDLESEX	:

 

On this, the 8th day
of October, 2018, before me, a Notary Public in and for the State of New Jersey, personally appeared _________________, who acknowledged
himself to be the _________ of BLONDER TONGUE LABORATORIES, INC., a New Jersey corporation, and that he as such officer, being
authorized to do so, executed the foregoing instrument for the purposes therein contained by signing the name of the corporation
by himself as ____________________ for the purposes therein contained.

 

IN WITNESS WHEREOF,
I hereunto set my hand and official seal.

 

	 	 
	 	Notary Public

 

My Commission Expires:

 

	STATE OF NEW YORK	:
	 	:  ss
	COUNTY OF _____________	:

 

On this, the ________
day of October, 2018, before me, a Notary Public in and for the State of New Jersey, personally appeared _________________, who
acknowledged himself to be the _________ of JAKE BROWN RD, LLC, a New limited liability company, and that he as such ______, being
authorized to do so, executed the foregoing instrument for the purposes therein contained by signing the name of the limited liability
company by himself as ____________________ for the purposes therein contained.

 

IN WITNESS WHEREOF,
I hereunto set my hand and official seal.

 

	 	 
	 	Notary Public

 

My Commission Expires:

 

     

     

    

 

EXHIBIT A

Legal Description

 

Real property in the Township of Old Bridge, County of Middlesex,
State of New Jersey, described as follows:

 

ALL THAT CERTAIN lot, piece or parcel of land, situate, lying
and being in the Township of Old Bridge, County of Middlesex, State of New Jersey:

 

BEGINNING at a point in the Easterly line of Jake Brown Road,
variable width, distant 346.37 feet on a course bearing North 06 degrees 50 minutes 00 seconds East, from the intersection of the
said line of Jake Brown Road extended Southerly with the Northerly line of Patio Greens Drive, extended Westerly, and running;
thence

 

1. North 06 degrees 50 minutes 00 second East, 32.39 feet along
the Easterly line of Jake Brown Road, as shown on a plat entitled Final Map Section 2 Patio Greens dated 9/5/84, filed with the
Middlesex County Clerk on 8/20/85 as Map No. 4886, File No. 972, to a point of curvature; thence

 

2. Northerly along a curve to the left, having a radius of 1,000.00
feet, an arc length of 76.55 feet to a point of tangency; thence

 

3. North 02 degrees 26 minutes 50 seconds East, 541.66 feet
along the Easterly line of Jake Brown Road to a point of curvature, being the beginning of the second course in Deed Book 2669,
Page 827; thence

 

4. Northeasterly along a curve to the right, having a radius
of 50.00 feet, an arc length of 78.54 feet to a point of tangency; thence

 

5. South 87 degrees 33 minutes 10 seconds East, 792.91 feet
along the Southerly line of Jake Brown Road to a point of curvature; thence

 

6. Easterly along a curve to the left, having a radius of 200.00
feet, an arc length of 210.90 feet to a point of tangency; thence

 

7. North 32 degrees 01 minutes 44 seconds East, 244.08 feet
to a point in the Easterly line of the present Jake Brown Road and the old Jake Brown Road, being the terminus of the 6th course
in Deed Book 2660, Page 86, thence

 

8. South 53 degrees 58 minutes 40 seconds East, 396.54 feet
along the line of Lot 9 to a point; thence

 

9. South 44 degrees 50 minutes 00 seconds West, 189.49 feet
along the line of Lot 1 in Block 9002 as shown on a plat entitled Final Map Section 3 Patio Greens dated 3/31/82, filed in the
Middlesex County Clerk's Office on 4/19/84 as Map No. 4690, File No. 970; thence

 

10. South 43 degrees 03 minutes 07 seconds West, 849.65 feet
to a point, said point being 9.25 feet Easterly of the point of beginning in the Deed Book 3289, Page 68 and 9.25 feet Westerly
of the terminus of the 3rd course in Deed Book 3289, Page 68, Tract 2; thence

 

11. North 88 degrees 14 minutes 26 seconds West, 792.62 feet
to a point, being the point and place of beginning.

 

NOTE: FOR INFORMATION ONLY: Being Lot(s) 8, Block(s) 9000; Tax
Map of the Township of Old Bridge, County of Middlesex, State of New Jersey.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00288-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00288-of-00352.parquet"}]]